INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) with or without Copegus in Interferon Naïve HCV Genotype 1 Infected Patients

Trial Profile

INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) with or without Copegus in Interferon Naïve HCV Genotype 1 Infected Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2016

At a glance

  • Drugs Danoprevir (Primary) ; Mericitabine (Primary) ; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INFORM-SVR
  • Sponsors Roche
  • Most Recent Events

    • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Feb 2013 Planned end date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 04 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top